Cash In On Peanut Allergies.

Here is an interesting article in the Wall Street Journal about the emergence of companies focusing research on cures for autoimmune diseases in children as highly viable stock options for investors (for the non-medically minded, autoimmune diseases are ones caused by some sort of genetic or environmental factor other than a bacteria or virus, like food allergies or asthma). This is an issue that’s particularly close to my heart, as autoimmune research is some research I would like to do when I graduate, and it also serves as a very powerful segue into another argument of mine, that there is room for the free market in medical research. Article here.

Author

  • Cornell students, community members, and alumni contribute to the Cornell Review. Staff consists of student writers collaborating on articles, with occasional guest submissions as well.

    View all posts

Related